Anticancer Drugs Oncology Pasireotide Pharmacology Physiotherapy


In this article we will discuss Pasireotide
(Dosage Overview)

In this article, we will discuss Pasireotide (Dosage Overview). So, let’s get started.


Cushing’s Disease
Pasireotide is indicated for the treatment of adult patients with Cushing’s disease for whom pituitary surgery is not an option or has not been curative.


Recommended Dosage Range
The recommended dosage range of Pasireotide is 0.3 to 0.9 mg by subcutaneous injection twice a day.
The recommended initial dose is either 0.6 mg or 0.9 mg twice a day. Titrate dose based on response and tolerability.

Patients should be evaluated for a treatment response [clinically meaningful reduction in 24-hour urinary free cortisol (UFC) levels and/or improvement in signs or symptoms of the disease] and should continue receiving therapy with Pasireotide as long as benefit is derived. Maximum urinary free cortisol reduction is typically seen by two months of treatment. For patients who are started on 0.6 mg twice a day, a dosage increase to 0.9 mg twice a day may be considered based on the response to the treatment, as long as the 0.6 mg dosage is well tolerated by the patient.
Management of suspected adverse reactions may require temporary dose reduction of Pasireotide. Dose reduction by 0.3 mg decrements per injection is suggested.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.